The MajesTEC-3 phase 3 trial reveals striking efficacy data for teclistamab in patients with multiple myeloma previously treated with one to three therapy lines. Among the 740 trial participants, teclistamab reduced the risk of disease progression or death by 70 percent relative to standard care treatments, establishing a meaningful statistical and clinical advantage.
Complete response rates demonstrated a particularly impressive differential, with teclistamab achieving 26.5% compared with 10.2% in the control arm—a more than twofold increase. The overall response rate reached 61.3% with teclistamab versus 41.9% with standard treatments. These quantifiable improvements in both response depth and durability underscore the bispecific antibody’s potential to transform treatment outcomes for earlier-line myeloma patients, supporting the clinical rationale for repositioning this therapeutic class within standard care algorithms.
Read the full article on GMJ Newsroom.
Was this article helpful?
